Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference
A live audio webcast of the presentation will be available on the "Investors & Media" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.
Kodiak (Nasdaq: KOD) is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in
"Kodiak," "ABC Platform" and the Kodiak logo are registered trademarks or trademarks of
John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, email@example.com